Trizivir and Conjunctival hyperaemia - a phase IV clinical study of FDA data


Conjunctival hyperaemia is reported only by a few people who take Trizivir.

The phase IV clinical study analyzes which people take Trizivir and have Conjunctival hyperaemia. It is created by eHealthMe based on reports of 2,658 people who have side effects while taking Trizivir from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

2,658 people reported to have side effects when taking Trizivir.
Among them, 3 people (0.11%) have Conjunctival hyperaemia.

What is Trizivir?

Trizivir has active ingredients of abacavir sulfate; lamivudine; zidovudine. It is often used in hiv infection. eHealthMe is studying from 2,670 Trizivir users for its effectiveness, alternative drugs and more.

What is Conjunctival hyperaemia?

Conjunctival hyperaemia (congestion of conjunctival vessels) is found to be associated with 901 drugs and 587 conditions by eHealthMe.

Number of Trizivir and Conjunctival hyperaemia reports submitted per year:

Could Trizivir cause Conjunctival hyperaemia?

Time on Trizivir when people have Conjunctival hyperaemia *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 100 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Conjunctival hyperaemia when taking Trizivir *:

  • female: 33.33 %
  • male: 66.67 %

Age of people who have Conjunctival hyperaemia when taking Trizivir *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 100 %
  • 50-59: 0.0 %
  • 60+: 0.0 %

Common drugs people take besides Trizivir *:

  1. Viramune: 3 people, 100.00%
  2. Omeprazole: 1 person, 33.33%
  3. Epzicom: 1 person, 33.33%

Common side effects people have besides Conjunctival hyperaemia *:

  1. Cheilitis (infection of lips): 3 people, 100.00%
  2. Rashes (redness): 3 people, 100.00%
  3. Erythema Multiforme (a type of hypersensitivity reaction): 3 people, 100.00%
  4. Swallowing Pain Or Burning: 3 people, 100.00%
  5. Swallowing Difficulty: 3 people, 100.00%
  6. Fever: 3 people, 100.00%
  7. Purpura (purplish discoloration of the skin): 3 people, 100.00%
  8. Rash Maculo-Papular (red area on the skin that is covered with small confluent bumps): 3 people, 100.00%
  9. Oral Mucosal Erythema (redness of the mucous membrane of mouth): 2 people, 66.67%
  10. Palmar-Plantar Erythrodysaesthesia Syndrome (hand-foot syndrome): 2 people, 66.67%

* Approximation only. Some reports may have incomplete information.

Do you take Trizivir and have Conjunctival hyperaemia?

Check whether Conjunctival hyperaemia is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Conjunctival hyperaemia and when was it recovered:

Expand to all the drugs that have ingredients of abacavir sulfate; lamivudine; zidovudine:

Alternative drugs to, pros and cons of Trizivir:

Common Trizivir side effects:

Browse all side effects of Trizivir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Conjunctival hyperaemia treatments and more:

COVID vaccines that are related to Conjunctival hyperaemia:

Common drugs associated with Conjunctival hyperaemia:

All the drugs that are associated with Conjunctival hyperaemia:

Common conditions associated with Conjunctival hyperaemia:

All the conditions that are associated with Conjunctival hyperaemia:

How the study uses the data?

The study uses data from the FDA. It is based on abacavir sulfate; lamivudine; zidovudine (the active ingredients of Trizivir) and Trizivir (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: